According to the company, the trial did not demonstrate efficacy on the key clinical endpoints and will not advance THR-687 to Part B of the trial. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of patients with DME.
The cataract surgery process continues to become more refined.
Patients are at risk for developing severe dry eye and ocular surface disease.
Learn about a novel procedure using a template prosthesis to facilitate intraoperative adjustment during external levator resection ptosis repair.
Aurion noted that its first candidate is a cell therapy for the treatment of corneal edema secondary to endothelial dysfunction.
A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.
Bath was recognized as the first Black woman physician to receive a medical patent, as well as the first woman to lead a post-graduate training program in ophthalmology. She joins four other inventors as the most recent inductees into the Hall.
Alex Dastgheib, MD, ABO, discusses the findings of the paper, "325 Cases of Phacoemulsification in Blind Cataracts," presented at the 2022 ASCRS conference in Washington, DC. The paper won the Challenging Cases session during the meeting.
Newer generation formulas generally outperformed older generation formulas, with SRK/T performing the best of older formulas, especially when using TK values.
In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.
Lens thickness and anterior chamber duct values obtained by Lenstar can be improved by SpikeFinder to reduce errors in measurements.
The grant, awarded by the National Institute of General Medical Sciences, a program of the NIH, will help West Virginia University investigators develop innovative ways to prevent, treat and slow the progression of vision problems that are currently incurable.
Variable TULP1 missense mutations in inherited retinal diseases.
Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.
Jonathan Solomon, MD, shares his personal experience using the Beyeonics One exoscope, highlighting what makes this tool stand out.
Edward Hu, MD, PhD, looked at 812 toric IOLs utilized of various platforms, concluding a low total toric rotation rate at 2.1%.
The study assesses and compares the accuracy of IOL formulas using keratometry (K) and total keratometry (TK) values obtained by a swept-source OCT biometer (IOL Master 700) in eyes with previous PKP prior to cataract surgery.
There is considerable variability in variables when measuring the eyes with both biometers, which may affect formula performance and postoperative refractive predictions when using formulas that utilize values like interior chamber depth and lens thickness.
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Eva Chamorro, PhD, MSc, points out that myopia control spectacle lenses affect the diurnal rhythms in the AL in young adult human and produced a small short-term increase in the AL that varies in intensity and time interval for each of the 3 studied lenses.
Christina Herrspiegel, MD, and colleagues from the Karolinska Institute and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.
The project, presented by Colton Hill, MPH, on behalf of the Dean McGee Eye Institute, looks at complication rates during cataract surgery or after cataract surgery for patients with prior intravitreal injections or incisional retinal procedures.
THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.
Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.
Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.
Technical details, communication style key to presbyopia-correcting IOL journey.
Daniel Choi, MD, and colleagues from the University of Pennsylvania, Philadelphia, investigated the effect of anti-vascular endothelial growth factor (VEGF) therapies in patients.
During a presentation at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Yuichi Hori, MD, PhD, and colleagues found that taping the top border of a surgical mask to a clinicians’ skin reduces the potential for ocular surface damage resulting from expirations of air reaching the ocular surface during the COVID-19 pandemic.
Allie Holmes, head of US marketing for Johnson & Johnson Surgical Vision, shares an update on what visioning the company is doing with their new and elevated technologies.
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.
Expansion of program aims to provide more children with improved eye care; enhance the teaching of Wills residents and fellows
